Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VOR Vor Biopharma Inc.

Post-Mkt 03-10 19:16:02 EDT

16.00

+0.54

+3.49%

盘后15.91

-0.09-0.56%

18:39 EDT

High16.74	Low15.39	Vol758.88K
Open15.39	D1 Closing15.46	Amplitude8.73%
Mkt Cap664.32M	Tradable Cap303.54M	Total Shares41.52M
T/O12.22M	T/O Rate4.00%	Tradable Shares18.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VOR","market":"US","secType":"STK","nameCN":"Vor Biopharma Inc.","latestPrice":16,"timestamp":1773172800000,"preClose":15.46,"halted":0,"volume":758879,"hourTrading":{"tag":"盘后","latestPrice":15.91,"preClose":16,"latestTime":"18:39 EDT","volume":7420,"amount":118643.78918,"timestamp":1773182340512,"change":-0.09,"changeRate":-0.005625,"amplitude":0.01875},"delay":0,"changeRate":0.03492884864165583,"floatShares":18971400,"shares":41519800,"eps":-386.86,"marketStatus":"Post-Mkt","change":0.54,"latestTime":"03-10 19:16:02 EDT","open":15.39,"high":16.74,"low":15.39,"amount":12224916.132583,"amplitude":0.087322,"askPrice":16.21,"askSize":97,"bidPrice":15.9,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-386.86,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773187200000},"marketStatusCode":4,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":15.46,"preHourTrading":{"tag":"盘前","latestPrice":15.21,"preClose":15.46,"latestTime":"09:22 EDT","volume":976,"amount":14987.830784,"timestamp":1773148969651,"change":-0.25,"changeRate":-0.016171,"amplitude":0.013583},"postHourTrading":{"tag":"盘后","latestPrice":15.91,"preClose":16,"latestTime":"18:39 EDT","volume":7420,"amount":118643.78918,"timestamp":1773182340512,"change":-0.09,"changeRate":-0.005625,"amplitude":0.01875},"volumeRatio":1.328403,"impliedVol":1.3167,"impliedVolPercentile":0.4552},"requestUrl":"/m/hq/s/VOR/wiki","defaultTab":"wiki","newsList":[{"id":"2614083787","title":"RemeGen FY2025 revenue CNY3.3bn up 89.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083787","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614083787?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:15","pubTimestamp":1772190938,"startTime":"0","endTime":"0","summary":"RemeGen reported preliminary FY 2025 results with total revenue of CNY 3.3 billion, up 89.4%. Operating profit was CNY 721.4 million, while net income attributable to shareholders was CNY 708.5 million; net income attributable to shareholders excluding non-recurring items was CNY 65.1 million. Basic earnings per share were CNY 1.29 and weighted average return on net assets was 24.9%. Total assets were CNY 7.2 billion at year-end, up 31.7%, and parent equity was CNY 3.6 billion, up 81.4%; net assets per share were CNY 6.72, up 82.1%. RemeGen said growth was driven by rapidly rising PRC sales of its core products telitacicept and disitamab vedotin, and higher technology licensing revenue after granting Vor Biopharma exclusive rights to develop and commercialize telitacicept worldwide excluding Greater China. The company also cited lower unit production costs, improving gross margins, a lower sales expense ratio, and reduced overseas R&D expenses linked to the telitacicept licensing. It a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL6zzfW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","BK0239","BK4139","688331","LU2148510915.USD","LU2488822045.USD","LU1064131003.USD","VOR"],"gpt_icon":0},{"id":"2607105997","title":"Vor Biopharma Inc - Prospectus for Resale of 13.9 Mln Shares of Common Stock by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607105997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607105997?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:16","pubTimestamp":1769721374,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU17Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2603336589","title":"Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603336589","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603336589?lang=en_us&edition=fundamental","pubTime":"2026-01-16 04:06","pubTimestamp":1768507590,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc. presented updates on its lead autoimmune programs targeting B cell-driven diseases through BAFF/APRIL inhibition with telitacicept, a selective BAFF/APRIL inhibitor. The company highlighted ongoing and upcoming global Phase 3 clinical trials in myasthenia gravis, with topline data expected in the first half of 2027, and in Sjgren's disease, which is set to begin in the first half of 2026. Telitacicept has shown clinical validation across more than eight autoimmune indications in China and has been administered to tens of thousands of patients with a manageable safety and tolerability profile. Adverse events reported in clinical trials were primarily mild to moderate, including upper respiratory tract infection, injection site reaction, urinary tract infection, cough, and diarrhea. The company reported a strong cash position of $450 million as of December 2025, expected to fund operations into mid-2028. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL3bM2n3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2602541336","title":"Vor Biopharma to Highlight Telitacicept at JPM Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602541336","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602541336?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:18","pubTimestamp":1768231097,"startTime":"0","endTime":"0","summary":"Vor Biopharma ( ($VOR) ) has provided an update. Vor Biopharma announced that it will present and host one-on-one investor meetings at the 44th Ann...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-to-highlight-telitacicept-at-jpm-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-to-highlight-telitacicept-at-jpm-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345769128.USD","LU1988902786.USD","LU0208291251.USD","LU2357305700.SGD","LU0211328371.USD","LU0820561818.USD","LU2237443895.HKD","LU0265550359.USD","LU2381873111.SGD","SG9999002224.SGD","LU1974910355.USD","IE0034235188.USD","IE000M9KFDE8.USD","IE00BDCRKT87.USD","LU2242649171.HKD","LU0345770993.USD","LU1261432733.SGD","LU2417539215.USD","IE00BJTD4V19.USD","IE00BJTD4N35.SGD","IE00BWXC8680.SGD","LU0345769631.USD","VOR","LU1032466523.USD","LU1670627923.USD","LU1244550221.USD","LU2237443382.USD","LU1894683348.USD","LU0170899867.USD","LU0964807845.USD","IE00B1BXHZ80.USD","LU2462157665.USD","IE00B775SV38.USD","IE00B1XK9C88.USD","IE00BYXW3230.USD","LU2211815571.USD","IE00B3S45H60.SGD","LU1917777945.USD","IE00BLSP4452.SGD","LU2756315318.SGD","IE00BZ1G4Q59.USD","LU0006306889.USD","LU2264538146.SGD","LU0345770308.USD","LU1548497426.USD","IE00BKDWB100.SGD","LU2213496289.HKD","LU1162221912.USD","SG9999002232.USD","LU0106831901.USD"],"gpt_icon":0},{"id":"2602937514","title":"Vor Biopharma Initiated at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2602937514","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602937514?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:57","pubTimestamp":1767963420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 07:57 ET (12:57 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2602327422","title":"Vor Biopharma Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602327422?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:18","pubTimestamp":1767957538,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA13J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2602097327","title":"Vor Bio initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2602097327","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602097327?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:15","pubTimestamp":1767957337,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham initiated coverage of Vor Bio (VOR) with a Buy rating and $50 price target The firm believes the company is positioned t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vor-bio-initiated-with-a-buy-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vor-bio-initiated-with-a-buy-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2600098258","title":"Vor Biopharma Announces Separation Agreement With Chief Development Officer Qing Zuraw","url":"https://stock-news.laohu8.com/highlight/detail?id=2600098258","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600098258?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:02","pubTimestamp":1767387737,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc. announced that Dr. Qing Zuraw, the company's Chief Development Officer, has departed the company as of December 31, 2025, following her decision to pursue other opportunities. Under the terms of a separation agreement, Dr. Zuraw will receive severance benefits consistent with a resignation during the specified period, as outlined in her employment agreement dated July 17, 2025, and its amendment from November 2, 2025. The agreement also includes a general release of claims, a 12-month non-compete clause, and customary non-disparagement and confidentiality covenants. Vor Biopharma expects to enter into a consulting arrangement with Dr. Zuraw to assist with the transition in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLjcgtd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2600098839","title":"Getty Images, Torm, and More Stocks See Action From Activist Investors -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2600098839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600098839?lang=en_us&edition=fundamental","pubTime":"2026-01-03 04:22","pubTimestamp":1767385320,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Dec. 25 through Dec. 31, 2025. Source: VerityData. Getty Images Holdings  Neuberger Berman reduced its stake in the digital image marketplace operator to 55,213,295 shares. Neuberger Berman did so through the open market sale of 3,470,917 Getty Images shares on Oct. 31 at per share prices ranging from $1.97 to $2.75, as well as a pro rata in-kind distribution of 15,428,050 shares to limited partners on Dec. 17. Following the latest activity, Neuberger continues to ow","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0997586861.USD","BK4231","RXRX","CAMP","BK4611","BK4020","BK4539","BK4080","BK4139","BK4548","BK4211","BK4077","BK4144","BK4588","GETY","TRMD","BK4609","VOR","BK4585"],"gpt_icon":0},{"id":"2593448758","title":"Vor Biopharma Adds Andrew Levin and Wouter Joustra to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448758","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448758?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:01","pubTimestamp":1766523668,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc. has appointed Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Dr. Levin replaces Sarah Reed, who resigned from the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL5g0G1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","LU2210149790.SGD","LU2210150020.SGD","VOR","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","LU0314104364.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2593448782","title":"Vor Bio Appoints Ra Capital’s Andrew Levin, M.d., Ph.d., and Forbion’s Wouter Joustra to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448782","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448782?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:01","pubTimestamp":1766523660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUA9RJRZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2592113505","title":"Vor Biopharma Inc. Files Initial Statement of Beneficial Ownership for Director Andrew David Levin","url":"https://stock-news.laohu8.com/highlight/detail?id=2592113505","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592113505?lang=en_us&edition=fundamental","pubTime":"2025-12-20 07:05","pubTimestamp":1766185520,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Andrew David Levin as the beneficial owner in his role as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL5DqG9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vor Biopharma Inc. Files Initial Statement of Beneficial Ownership for Director Andrew David Levin","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2592091186","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091186?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:40","pubTimestamp":1765986030,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocksEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCCO","KYMR","COR","APOG","XENE","VOR","VSCO","HOOD","DHR","FISI","KYTX","NFE","ABM","CYTK","NEO","PANW","SPOT","AVTR","LNG","CVX","COUR","HUT","FCF","XOM","FDX","TXRH","WSBC","ALB","NWBI","PSKY","HL","JBL","WMB","COP","FTNT","WAT","IMNM","VERU","NEM","GIS","MCK","CNX","TPL","FCX","CVS","NUE"],"gpt_icon":1},{"id":"2592197879","title":"Vor Biopharma Initiated at Buy by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2592197879","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592197879?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:30","pubTimestamp":1765985400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 10:30 ET (15:30 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COWN","BK4139","TD","BK4207","VOR","BK4585","BK4127","BK4566"],"gpt_icon":0},{"id":"2592191575","title":"Vor Biopharma Shares up 1.6% After TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592191575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592191575?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:31","pubTimestamp":1765981863,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4N3XN18E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2592913067","title":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse","url":"https://stock-news.laohu8.com/highlight/detail?id=2592913067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592913067?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:14","pubTimestamp":1765980847,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas RoadhouseEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","AIR","COR","LU2063271972.USD","FCX","IMNM","USAW.SI","FDX","ALB","PANW","FCF","PSKY","UDMY","FISI","VERU","CYTK","XENE","VOR","NUE","NEO","COUR","APOG","FTNT","CDE","TE","STLD","HL","TPL","SCCO","LU2750360641.GBP","WSBC","NEM","JBL","AVTR","GIS","MCK","DHR","TXRH","HUT","ABM","CVS","KOD","VSCO","NWBI","WAT"],"gpt_icon":1},{"id":"2592907639","title":"BUZZ-Vor Bio jumps after TD Cowen initiates coverage with 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2592907639","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592907639?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:13","pubTimestamp":1765977224,"startTime":"0","endTime":"0","summary":"BUZZ-Vor Bio jumps after TD Cowen initiates coverage with 'buy'** Shares of drug developer Vor Biopharma VOR.O up 5.6% at $16.72 premarket** Brokerage TD Cowen initiates coverage with \"buy\", citing strong data for VOR's lead autoimmune drug, telitacicept and differentiated dual mechanism** Telitacicept is being developed to treat Myasthenia Gravis, a muscle weakening disorder, and primary Sjgren's Disease, condition that causes dry eyes and mouth** Notes favorable safety profile and global late-stage trials, with topline data expected in 2027–28, brokerage said** Telitacicept is already approved in China for lupus , rheumatoid arthritis  and generalized myasthenia gravis , and the company has filed for approval in IgA nephropathy  and Sjgren's disease** In China late-stage trial, telitacicept helped patients improve by 4.8 points more than placebo on a key scale, which the brokerage calls \"best-in-disease efficacy among all approved agents and those in development to date\"** Telitacice","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2592997706","title":"TD Cowen Initiates Vor Biopharma at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997706?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:48","pubTimestamp":1765975727,"startTime":"0","endTime":"0","summary":"Vor Biopharma (VOR) has an average rating of overweight and mean price target of $40.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4127","COWN","TD","BK4566","BK4207","BK4139","VOR","BK4585"],"gpt_icon":0},{"id":"2592999950","title":"Vor Biopharma Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592999950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592999950?lang=en_us&edition=fundamental","pubTime":"2025-12-17 18:41","pubTimestamp":1765968118,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2591647836","title":"Vor Biopharma Launches $150 Million Private Placement; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647836","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647836?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:45","pubTimestamp":1765809919,"startTime":"0","endTime":"0","summary":"Vor Biopharma  said Monday it agreed to sell about 13.9 million shares in a private placement to institutional investors priced at $10.81 a share.The offering is expected to raise gross proceeds of about $150 million and is slated to close on Thursday, the company said.The financing includes participation from RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital and Venrock Healthcare Capital Partners, the company said, adding that Forbion is being granted the right to appoint one director to its board.Vor said it plans to use the proceeds to support development of telitacicept, including its ongoing global phase 3 trial in myasthenia gravis and a planned global phase 3 trial in primary Sjogren's disease.Vor Biopharma shares were more than 7% higher in recent trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VOR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vorbio.com","stockEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":0.1748},{"period":"3month","weight":0.4422},{"period":"6month","weight":-0.5706},{"period":"1year","weight":-0.227},{"period":"ytd","weight":0.182}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.04043},{"month":2,"riseRate":0.6,"avgChangeRate":0.020325},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.118708},{"month":4,"riseRate":0,"avgChangeRate":-0.179628},{"month":5,"riseRate":0.2,"avgChangeRate":-0.276218},{"month":6,"riseRate":0.4,"avgChangeRate":1.31333},{"month":7,"riseRate":0.2,"avgChangeRate":-0.043439},{"month":8,"riseRate":0.4,"avgChangeRate":0.001368},{"month":9,"riseRate":0.4,"avgChangeRate":-0.0543},{"month":10,"riseRate":0.6,"avgChangeRate":-0.046096},{"month":11,"riseRate":0.2,"avgChangeRate":-0.192554},{"month":12,"riseRate":1,"avgChangeRate":0.3146}],"exchange":"NASDAQ","name":"Vor Biopharma Inc.","nameEN":"Vor Biopharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vor Biopharma Inc.,VOR,Vor Biopharma Inc.股票,Vor Biopharma Inc.股票老虎,Vor Biopharma Inc.股票老虎国际,Vor Biopharma Inc.行情,Vor Biopharma Inc.股票行情,Vor Biopharma Inc.股价,Vor Biopharma Inc.股市,Vor Biopharma Inc.股票价格,Vor Biopharma Inc.股票交易,Vor Biopharma Inc.股票购买,Vor Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}